US 10,376,490 B2
Pharmaceutical composition containing silybin
Naifeng Wu, Tianjin (CN); Xijun Yan, Tianjin (CN); He Sun, Tianjin (CN); Kaijing Yan, Tianjin (CN); Yonghong Zhu, Tianjin (CN); Shunnan Zhang, Tianjin (CN); Xiaolin Bai, Tianjin (CN); Yi He, Tianjin (CN); Xiaohui Ma, Tianjin (CN); and Ting Li, Tianjin (CN)
Assigned to Tasly Pharmaceutical Group Co., Ltd., Tianjin (CN)
Appl. No. 15/560,578
Filed by TASLY PHARMACEUTICAL GROUP CO., LTD., Tianjin (CN)
PCT Filed Mar. 22, 2016, PCT No. PCT/CN2016/077039
§ 371(c)(1), (2) Date Sep. 22, 2017,
PCT Pub. No. WO2016/150380, PCT Pub. Date Sep. 29, 2016.
Claims priority of application No. 2015 1 0127265 (CN), filed on Mar. 23, 2015.
Prior Publication US 2018/0042893 A1, Feb. 15, 2018
Int. Cl. A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 36/82 (2006.01); A61K 47/24 (2006.01); B65D 81/32 (2006.01); A61K 31/357 (2006.01)
CPC A61K 31/357 (2013.01) [A61K 9/0095 (2013.01); A61K 9/145 (2013.01); A61K 9/1617 (2013.01); A61K 9/2013 (2013.01); A61K 9/4858 (2013.01); A61K 36/82 (2013.01); A61K 47/24 (2013.01); B65D 81/32 (2013.01); A61K 2236/19 (2013.01)] 17 Claims
 
1. A pharmaceutical composition comprising
biologically active ingredients consisting of a silybin-phospholipid complex pharmaceutical preparation and a Pu'er tea essence or aqueous extract,
wherein the silybin-phospholipid complex pharmaceutical preparation and the Pu'er tea essence or aqueous extract are each contained in separate packages according to unit dose,
wherein the separate packages are further contained in a single package,
wherein the ratio of the silybin-phospholipid complex to the Pu'er tea essence or Pu'er tea extract is 0.5-2.5:0.3-10 (w:w),
wherein the silybin-phospholipid complex pharmaceutical preparation and the Pu'er tea essence or aqueous extract are administrated in a combination according to respective doses to a subject in need thereof.